Cancer blood test fails to catch disease earlier in major study
medicalxpress - A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it.
AI Summary: A large trial evaluating GRAIL’s multi‑cancer blood screening test failed to meet its primary goal of earlier cancer detection. The disappointing result casts doubt on the test’s clinical utility for population screening, sparks debate over marketing and clinical use, and prompts calls for clearer evidence before widespread adoption.
Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
Elizabeth Cairns / endpoints - Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday. Patients in the REDEFINE 4 ...
AI Summary: In a direct comparator study, Eli Lilly’s marketed obesity drug Zepbound produced greater mean weight loss than Novo Nordisk’s experimental CagriSema. The result complicates the competitive landscape for anti‑obesity medicines and will influence prescribers, payers and the almighty market share tussle.
More Research, Less Cancer: £250m raised to transform the future of cancer research
Charlotte Mathé / cancerresearchuk - We’ve reached an incredible moment - £250m raised for our More Research, Less Cancer campaign. This milestone brings us more than halfway to our £400m goal and accelerates our mission to prevent, detect and treat cancer earlier and more effectively. The p…
AI Summary: The More Research Less Cancer campaign has reached a £250 million fundraising milestone to accelerate cancer research, support translational projects, and expand patient-focused initiatives. Donor momentum will underwrite discovery science and clinical translation, giving researchers more runway to turn promising lab findings into treatments patients might actually see.
FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases 2026
oncodaily - The U.S. Food and Drug Administration (FDA) has released groundbreaking draft guidance introducing a new regulatory framework designed to accelerate the development and approval of individualized therapies for patients with […]
AI Summary: The FDA released draft guidance creating a regulatory pathway to speed individualized and N-of-1 cell and gene therapies for ultra‑rare diseases. The framework clarifies evidence expectations, manufacturing and safety-monitoring options, and trial design flexibility to help get bespoke treatments from bench to bedside faster — no miracles promised, just fewer bureaucratic speed bumps.
ChatGPT Health performance in a structured test of triage recommendations
Ashwin Ramaswamy / nature - Nature Medicine, Published online: 23 February 2026; doi:10.1038/s41591-026-04297-7A stress test of ChatGPT Health triage revealed missed high-risk emergencies and inconsistent activation of suicide-crisis safeguards, raising safety concerns for consumer-…
AI Summary: A structured, independent evaluation found that ChatGPT Health—an AI tool offering consumer triage and health guidance—missed or misclassified high-risk cases and gave inconsistent advice. Researchers and clinicians raised safety concerns about relying on the system for urgent medical decision-making, calling for tighter oversight and validation before broad public deployment.
Gilead to acquire cell therapy manufacturer for $7.8B
Paige Twenter / beckershospitalreview - In a deal worth $7.8 billion, Gilead Sciences has entered a definitive agreement to acquire Arcellx, a biotech company developing a cell therapy for multiple myeloma. Gilead announced the acquisition agreement a few months after Arcellx published positive…
AI Summary: Gilead Sciences agreed to acquire Arcellx for $7.8 billion to secure manufacturing and commercialization of a leading multiple myeloma CAR‑T candidate. The deal folds Arcellx’s anito‑cel program into Gilead’s oncology portfolio, accelerating regulatory filings and scale‑up plans — because buying your way into cutting‑edge cell therapy apparently never goes out of style.
Justice Department sues OhioHealth over alleged anticompetitive insurer contracts
Sydney Halleman / healthcaredive - The DOJ filed a lawsuit last week accusing OhioHealth of leveraging its market power to force insurers to include its providers in their networks.
AI Summary: The Justice Department filed a civil antitrust suit accusing OhioHealth of using its market dominance to force insurers to include all system hospitals in provider networks, allegedly blocking lower‑cost plan options and harming competition. The case seeks to stop contract practices deemed exclusionary and could prompt changes in hospital‑insurer negotiation tactics.
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin
esmo - Findings from the KEYNOTE-905/EV-303 study
AI Summary: KEYNOTE‑905/EV‑303 results show perioperative enfortumab vedotin combined with pembrolizumab significantly improved event‑free survival, overall survival and pathological complete response in muscle‑invasive bladder cancer patients ineligible for cisplatin. The findings could shift neoadjuvant strategies for this high‑risk group and spur guideline updates and broader adoption in practice.
Data and Decisions in Advanced NSCLC at the 2026 TTLC Symposia – IASLC
oncodaily - International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn: “2026 TTLC Symposia Event Data and Decisions in Advanced NSCLC The treatment landscape for advanced NSCLC is evolving […]
AI Summary: TTLC 2026 brought together lung cancer experts to present symposia on advanced NSCLC topics — from RAS inhibition to mechanisms of EGFR resistance — and unveiled new clinical data. The meeting, including LungCancerRx LIVE Season 2 sessions, fostered debate, rapid data exchange and collaborations likely to steer upcoming trials and treatment approaches.
Brain injury is almost ten times more common in unhoused people. Addressing it is key to reducing homelessness
medicalxpress - On any given night, 60,000 people in Canada will go to sleep homeless. Research estimates that more than half of them have had a brain injury at one point in their lives, most of them being injured before becoming homeless. An estimated 22.5% live with mo…
AI Summary: Research indicates people experiencing homelessness suffer brain injuries at dramatically higher rates—approaching a tenfold increase—compared with housed populations. Advocates and clinicians call for routine screening, accessible neurorehabilitation, trauma-informed services and coordinated housing support to address long-term disability and reduce homelessness cycles. The findings argue treating injuries, not just symptoms, yields better social and health outcomes.
‘You’re not the Lone Ranger’ anymore: Medical education evolves for team-based care
Paige Twenter / beckershospitalreview - As U.S. healthcare increasingly adopts team-based care, medical schools are working to prepare students for future care delivery models, according to a Feb. 18 article from the Association of American Medical Colleges. Team-based care, or a coordinated ba…
AI Summary: A multi‑agent AI system called DeepRare has proven it can outpace physicians in head‑to‑head rare‑disease diagnosis tests, promising to shorten the notorious “diagnostic odyssey.” Industry leaders tout this as a practical diagnostic aid, while experts caution about validation, integration into clinical workflows and equity in access before it replaces any human judgment.
Optum unveils Value Connect, its AI-powered tool to support value-based care
fiercehealthcare - Optum is rolling out a new AI tool that aims to address some of the key barriers to value-based care, from data fragmentation to administrative burden.
AI Summary: Optum launched Value Connect, an AI-driven platform aimed at unifying fragmented payer and provider data to operationalize value-based care. The tool promises integrated data analytics, risk stratification, and workflow automation to reduce administrative friction and help health systems meet value contracts—essentially a tech fix for healthcare’s chronically leaky data plumbing.
A novel C. diff vaccine shows promise
Mariah Taylor / beckershospitalreview - Nashville, Tenn.-based Vanderbilt Health researchers have developed a promising novel vaccine to treat Clostridioides difficile infections. Previous vaccine strategies targeted the bacterium’s primary toxins, according to a Feb. 18 system news release. Th…
AI Summary: Researchers at Vanderbilt have reported a novel experimental vaccine that prevents Clostridioides difficile infection and reduces recurrence in early studies, demonstrating strong protective immune responses. The work offers a much‑needed alternative to antibiotics and recurrent‑infection management, though larger clinical trials will be required to confirm safety, durability and real‑world impact.
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Kyle LaHucik / endpoints - Novartis will pay $100 million upfront to tap into a macrocyclic peptide platform from Unnatural Products, a deal that could lead to new cardiovascular disease medicines. The move allows the Swiss pharma giant to delve ...
AI Summary: Novartis has committed $100 million upfront to partner with Unnatural Products, acquiring access to a macrocyclic peptide platform designed to reach challenging protein targets. The deal accelerates Novartis’ efforts to expand into next‑generation peptide therapeutics and bolsters its early R&D pipeline with technology aimed at previously “undruggable” targets.
Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA
Frank Vinluan / medcitynews - The FDA asked for more data to determine whether Disc Medicine’s bitopertin is benefiting patients with erythropoietic protoporphyria, a rare blood disorder. Analysts say it’s a surprising delay considering bitopertin is one of the first drugs in a new FD…
AI Summary: The FDA has rejected Disc Medicine’s application for its rare-disease candidate even after granting an accelerated review pathway, concluding the submitted evidence did not demonstrate sufficient benefit. The setback stalls a high-profile regulatory push and requires the company to collect more robust clinical data before re‑seeking approval.
Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks
Kellen K. Petersen / nature - Nature Medicine, Published online: 19 February 2026; doi:10.1038/s41591-026-04206-yPlasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimerʼs disease.
AI Summary: A Nature Medicine study presents plasma p‑tau217 “clocks” that estimate when symptomatic Alzheimer’s disease is likely to begin, offering a blood-based forecast years before cognitive decline appears. The test could reshape trial enrollment, early intervention timing and patient counseling—validation and access hurdles remain, but at least worried boomers get a calendar to dread.
Hims to buy Australia’s Eucalyptus for $240M upfront in global push
Ngai Yeung / endpoints - In a bid to build out its global presence, Hims is buying Australian digital health company Eucalyptus in a deal worth $240 million upfront. The deal announced Thursday morning would allow Hims to launch in ...
AI Summary: Hims & Hers is moving aggressively into international telehealth by acquiring Australia’s Eucalyptus, a deal various reports value in the low‑to‑mid hundreds of millions to over a billion depending on earnouts. The purchase gives the U.S. digital health company an immediate footprint in Australia, Japan and other markets as it chases global scale.
CDC confirms 910 measles cases in 2026; South Carolina remains hardest hit
Paige Twenter / beckershospitalreview - Six weeks into 2026, the CDC has confirmed 910 measles cases. If the pace of transmission continues, this year could far outpace the 2,280 cases detected across the U.S. in 2025, as 2026’s total is already 40% of 2025’s. The hardest-hit state is South Car…
AI Summary: The CDC has confirmed a nationwide uptick in measles cases, tallying hundreds of infections and triggering local public-health responses. Hotspots include a large South Carolina outbreak, an over‑40‑case cluster at a Florida college and a Los Angeles County case involving visits to LAX eateries while infectious. Officials urge vaccination and vigilance.
Prime Healthcare Foundation acquires Maine health system
Sydney Halleman / healthcaredive - Nonprofit Prime Foundation, an affiliate of for-profit hospital operator Prime Healthcare, now owns 21 hospitals across eight states.
AI Summary: Prime Healthcare Foundation finalized its acquisition of a Maine health system, marking another step in the organization's regional consolidation strategy. The deal adds hospitals to Prime’s portfolio and underscores ongoing consolidation trends as systems seek scale to manage financial and operational pressures.
Walgreens to lay off hundreds of employees
Dani James / healthcaredive - The drugstore retailer said it was simplifying its organization to speed up decision-making in a move impacting at least 600 workers.
AI Summary: Walgreens is planning significant staff reductions—hundreds of roles eliminated—as part of a corporate reorganization intended to simplify decision‑making and reduce costs under new ownership. The layoffs are concentrated across multiple states and reflect broader retail pharmacy cost‑cutting pressures.